Myotonic Dystrophy Research
Clinical activity in myotonic dystrophy type 1 and myotonic dystrophy type 2 focuses on the symptomatic treatment of myotonia, with attention to both short-term control and longer-term management in affected adults.
- DM1
- DM2
- Myotonia
The sponsor’s studies in this area address ongoing treatment needs for neuromuscular symptoms associated with inherited muscle disorders.
Non-Dystrophic Myotonias
Research in non-dystrophic myotonias includes myotonia congenita, paramyotonia congenita, and sodium channel myotonia, reflecting interest in disorders marked by impaired muscle relaxation and stiffness.
- Myotonia congenita
- Paramyotonia congenita
- Sodium channel myotonia
These programmes concentrate on symptomatic relief for adult patients living with channel-related muscle hyperexcitability conditions.
Neuromuscular Symptom Management
The funded trials emphasise treatment of muscle stiffness, delayed relaxation, and related functional impairment, with a therapeutic focus on improving daily symptom control in neuromuscular disease.
- Muscle stiffness
- Delayed muscle relaxation
- Functional impairment
This area reflects sustained interest in managing the core manifestations of myotonic disorders across distinct patient groups.
Mexiletine-Based Therapeutic Development
Current research centres on mexiletine in prolonged-release and immediate-release forms for symptomatic treatment of myotonia, indicating a strong therapeutic emphasis on anti-myotonic pharmacology.
- Prolonged-release mexiletine
- Immediate-release mexiletine
- Anti-myotonic therapy
The portfolio includes ongoing evaluation of tolerability and sustained symptom control in inherited muscle channel disorders.
